Gary Glick, Keith Flaherty Now Have $270m To Realize Their Vision For Precision Oncology 2.0™ — We’ll Just Have To Wait For The Details

Whatever investors have peeped about Gary Glick and Keith Flaherty’s game plan to bring about Precision Oncology 2.0, it’s good enough for a $162 million infusion into Scorpion Therapeutics just weeks after its $108 million Series A.